Corporate News
Date: Thursday, 22 September 2026Time of Reference: 09:51 PM Central Europe
Trading Performance
- Closing price (09:51 PM CET): USD 1.93
- Price change (24 h): –0.93 %
- Volume traded (last 24 h): USD 396.4 k
- Shares outstanding: 94.7 million
- Market capitalization: USD 202.2 million
- Simple moving average (200 days): USD 2.29
- 52‑week high: USD 3.24 (24 April 2026)
- 52‑week low: USD 1.43 (30 December 2025)
Since the close of the previous month, Compugen’s shares have declined by 14.86 %.
Comparative Performance
| Symbol | Change (24 h) | Current price | Market cap | PE ratio |
|---|---|---|---|---|
| PHOE.TA | +1.73 % | ILA 18,540 | ILA 15.4 bn | 14.45 |
| SLGL | –0.14 % | USD 65.1 | USD 215.5 mn | – |
| MZTF.TA | –0.25 % | ILA 23,410 | ILA 19.9 bn | 11.1 |
| CRNT | +0.5 % | USD 1.94 | USD 182.6 mn | – |
| ORMP | –0.24 % | USD 4.11 | USD 172.6 mn | 1.01 |
Market Context
During the recent trading session, Compugen Ltd. experienced a modest decline relative to the broader market. While the NASDAQ Composite showed moderate gains, Compugen’s performance was below the index average. No new corporate announcements or significant events were reported for the company during this period.
Company Overview
Compugen Ltd. is a pharmaceutical company focused on the discovery and development of genomics‑based drugs and diagnostic solutions for cancer treatment. The company operates globally, providing services aimed at advancing precision medicine.
